A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
Completed · Phase 1 · NCT06673238
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $30,420
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 95
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-722 (drug), Placebo (drug)
- Dates
- Started 2024-10-29; completion 2026-06-25
- Results posted
- Not yet
This is a Phase 1, first-in-human study to investigate safety, tolerability, and pharmacokinetics of ABBV-722 after oral dosing in healthy adult participants.
From ClinicalTrials.gov, last updated 2026-07-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $30,420 in research payments for this study in 2025 (17 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $30,420
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.